Bibliography
- Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars 2011;1:1-11
- Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010;10:1011-18
- Kresse GB. Biosimilars–science, status, and strategic perspective. Eur J Pharm Biopharm 2009;72:479-86
- Weise M, Bielsky MC, De Smet K, Biosimilar – why terminology matters. Nat Biotechnol 2011;29:690-3
- Available from: http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/BS2110Dft_guidelines_Final_HK_IK_29July_09.pdf
- Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-7
- Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol 2011;5:741-54
- Joshi SR. Biosimilar insulins: are they really 'similar'? J Assoc Physicians India 2009;57(Suppl):38-41
- Kramer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. BrJ Diabetes Vasc Dis 2010;10:163-71
- Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006;8:611-20
- Kannan V, Narayanaswamy P, Gadamsetty D, A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom 2009;23:1035-42
- Schmidt A, IDF 2011 Word Diabetes Congress Abstract Book (2011 International Diabetes Foundation), p. 466. Available from: http://conference2.idf.org/dubai2011/CM.NET.WebUI/CM.NET.WEBUI.SCPR/SCPRfunctiondetail.aspx?confID=05000000-0000-0000-0000-000000000001&sesID=05000000-0000-0000-0000-000000000509&absID=07000000-0000-0000-0000-000000002456 [Last accessed 19 January 2012]
- Casadevall N, Nataf J, Viron B, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
- Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-8
- Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005;16:S67-9
- Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80:88-92
- Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010;28:28-31
- Cheng SW, Lu J, Pan C, Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man. Chin J Diabetes 2010;18:387-93
- Verma M, Hazra P, Iyer H, Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries 2011;31:26-31
- Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Safety 2006;29:385-96
- Hasford J, Goettler M, Munter KH, Muller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002;55:945-50
- Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf [Last issued on 13 March 2012]